CH617350A5 - Process for the preparation of HB-Ag vaccines with high-level antibody formation - Google Patents
Process for the preparation of HB-Ag vaccines with high-level antibody formation Download PDFInfo
- Publication number
- CH617350A5 CH617350A5 CH1636974A CH1636974A CH617350A5 CH 617350 A5 CH617350 A5 CH 617350A5 CH 1636974 A CH1636974 A CH 1636974A CH 1636974 A CH1636974 A CH 1636974A CH 617350 A5 CH617350 A5 CH 617350A5
- Authority
- CH
- Switzerland
- Prior art keywords
- solution
- titer
- aqueous solution
- vaccines
- protein
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 39
- 229960005486 vaccine Drugs 0.000 title claims description 36
- 238000002360 preparation method Methods 0.000 title claims description 10
- 230000015572 biosynthetic process Effects 0.000 title claims description 9
- 239000000243 solution Substances 0.000 claims description 46
- 238000010438 heat treatment Methods 0.000 claims description 25
- 230000000890 antigenic effect Effects 0.000 claims description 13
- 102000004506 Blood Proteins Human genes 0.000 claims description 11
- 108010017384 Blood Proteins Proteins 0.000 claims description 11
- 239000007864 aqueous solution Substances 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 8
- 239000000872 buffer Substances 0.000 claims description 5
- 239000008363 phosphate buffer Substances 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 238000000502 dialysis Methods 0.000 claims description 2
- 238000011146 sterile filtration Methods 0.000 claims 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 18
- 239000004202 carbamide Substances 0.000 description 17
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 12
- 208000006454 hepatitis Diseases 0.000 description 10
- 231100000283 hepatitis Toxicity 0.000 description 10
- 241000282412 Homo Species 0.000 description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 6
- 229960004198 guanidine Drugs 0.000 description 6
- 108010088751 Albumins Proteins 0.000 description 5
- 102000009027 Albumins Human genes 0.000 description 5
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 5
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 5
- 235000011130 ammonium sulphate Nutrition 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 238000005194 fractionation Methods 0.000 description 4
- 229960000789 guanidine hydrochloride Drugs 0.000 description 4
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 102000008946 Fibrinogen Human genes 0.000 description 3
- 108010049003 Fibrinogen Proteins 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 241000473945 Theria <moth genus> Species 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 229940012952 fibrinogen Drugs 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 102000014702 Haptoglobin Human genes 0.000 description 2
- 108050005077 Haptoglobin Proteins 0.000 description 2
- 102000004338 Transferrin Human genes 0.000 description 2
- 108090000901 Transferrin Proteins 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229940031551 inactivated vaccine Drugs 0.000 description 2
- 229940102223 injectable solution Drugs 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000012581 transferrin Substances 0.000 description 2
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
- 102000006734 Beta-Globulins Human genes 0.000 description 1
- 108010087504 Beta-Globulins Proteins 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 229940028617 conventional vaccine Drugs 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960001269 glycine hydrochloride Drugs 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- CVGSWVDBRMDWPX-UHFFFAOYSA-N methanetriamine;hydrochloride Chemical compound Cl.NC(N)N CVGSWVDBRMDWPX-UHFFFAOYSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229940050527 other plasma protein fractions Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 108010058237 plasma protein fraction Proteins 0.000 description 1
- 229940081857 plasma protein fraction Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1161774A JPS5523254B2 (enrdf_load_stackoverflow) | 1974-01-28 | 1974-01-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH617350A5 true CH617350A5 (en) | 1980-05-30 |
Family
ID=11782869
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH1636974A CH617350A5 (en) | 1974-01-28 | 1974-12-10 | Process for the preparation of HB-Ag vaccines with high-level antibody formation |
Country Status (6)
| Country | Link |
|---|---|
| JP (1) | JPS5523254B2 (enrdf_load_stackoverflow) |
| CA (1) | CA1023662A (enrdf_load_stackoverflow) |
| CH (1) | CH617350A5 (enrdf_load_stackoverflow) |
| DE (1) | DE2440926C3 (enrdf_load_stackoverflow) |
| FR (1) | FR2258864B1 (enrdf_load_stackoverflow) |
| GB (1) | GB1462298A (enrdf_load_stackoverflow) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4017360A (en) * | 1975-05-14 | 1977-04-12 | Merck & Co., Inc. | Method for purifying hepatitis B antigen |
| GB1571829A (en) | 1976-04-06 | 1980-07-23 | Lafon Labor | Sulphur-containing diaryl compounds and oxygen-containing diaryl compounds |
| JPS591981B2 (ja) * | 1976-08-27 | 1984-01-14 | 株式会社ミドリ十字 | ＨＢｓ抗体検出用受身赤血球凝集試験用担体の製造方法 |
| US4639371A (en) * | 1984-10-02 | 1987-01-27 | New York Blood Center, Inc. | Hepatitis B antigenic compositions and vaccines against hepatitis B derived therefrom |
-
1974
- 1974-01-28 JP JP1161774A patent/JPS5523254B2/ja not_active Expired
- 1974-08-14 CA CA206,978A patent/CA1023662A/en not_active Expired
- 1974-08-15 GB GB3604674A patent/GB1462298A/en not_active Expired
- 1974-08-27 DE DE2440926A patent/DE2440926C3/de not_active Expired
- 1974-08-27 FR FR7429291A patent/FR2258864B1/fr not_active Expired
- 1974-12-10 CH CH1636974A patent/CH617350A5/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DE2440926B2 (de) | 1978-04-06 |
| GB1462298A (en) | 1977-01-19 |
| JPS50105817A (enrdf_load_stackoverflow) | 1975-08-20 |
| DE2440926C3 (de) | 1978-11-30 |
| FR2258864A1 (enrdf_load_stackoverflow) | 1975-08-22 |
| CA1023662A (en) | 1978-01-03 |
| JPS5523254B2 (enrdf_load_stackoverflow) | 1980-06-21 |
| DE2440926A1 (de) | 1975-07-31 |
| FR2258864B1 (enrdf_load_stackoverflow) | 1978-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2751717C2 (enrdf_load_stackoverflow) | ||
| DE2827027C3 (de) | Gefriergetrocknetes natives &Gamma;-globulin-Präparat zur intravenösen Verabreichung | |
| DE2324717B2 (de) | Verfahren zur Herstellung eines stabilen AHF-Konzentrates (Faktor VUI) | |
| DE2936047A1 (de) | Verfahren zur herstellung eines intravenoes verabreichbaren antikoerperhaeltigen immunglobulinpraeparates und danach hergestellte praeparate | |
| DE2624815B2 (de) | Herstellung einer injizierbaren, stromafreien und von Plasmaproteinen freien Hämoglobinlösung | |
| DE2433209A1 (de) | Hitzestabile plasmaproteinloesungen, verfahren zu ihrer herstellung und arzneipraeparate | |
| DE2403994A1 (de) | Herstellung von antisera | |
| DE2734150C3 (de) | Verfahren zur Herstellung von Human-Lysozympräparaten | |
| DE3152621C2 (enrdf_load_stackoverflow) | ||
| DE2639012C3 (de) | Inununtherapeutikum zur Prophylaxe und Therapie von Pseudomonas aeruginosa-Infektionen | |
| DE2658170A1 (de) | Arzneimittel zur behandlung der durch den hepatitisvirus b ausgeloesten akuten oder chronischen infektionen | |
| DE2835843A1 (de) | Verfahren zur herstellung einer fuer die intravenoese anwendung geeigneten gammaglobulinloesung | |
| CH617350A5 (en) | Process for the preparation of HB-Ag vaccines with high-level antibody formation | |
| DE3604947C2 (enrdf_load_stackoverflow) | ||
| DE2440927C3 (de) | Injizierbarer inaktivierter Impfstoff gegen Hepatitis B | |
| DE2703620C2 (de) | Verfahren zur Herstellung eines Konzentrats des Antihämophiliefaktors | |
| DE19600939C1 (de) | Verfahren zur Trennung von IgG und IgA | |
| DE2515666C3 (de) | Piasminreiche Gammaglobulinfraktion, Verfahren zu deren Herstellung und das Verfahrensprodukt enthaltendes Gammaglobulinpräparat | |
| DE2748520C2 (enrdf_load_stackoverflow) | ||
| DE2415079C3 (de) | Verfahren zum Isolieren von Albumin aus Blutplasma | |
| DE2532276C3 (de) | Verfahren zur Reinigung von Human-Antilymphozytenserum | |
| DE2409650A1 (de) | Waessrige haptoglobinloesungen, verfahren zu ihrer herstellung und arzneimittel | |
| DE3150935A1 (de) | Verfahren zur herstellung eines hepatitis-b impfstoffes | |
| AT387717B (de) | Verfahren zum bestimmen von unvertraeglichkeitsreaktionen verursachenden substanzen in therapeutisch und prophylaktisch anzuwendenden blutprodukten sowie verwendung des verfahrens | |
| Ziegler | Sodium dehydrocholate Its specific effect on pneumococci, II |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased | ||
| PL | Patent ceased |